Yahoo Finance

Vaccinex, Inc. to Present at the Clinical Trials on Alzheimer’s Disease (CTAD) Meeting

OC #24: SEMA4D blocking antibody, pepinemab, is a novel potential treatment for neurodegenerative disease: clinical proof of concept in Huntington’s Disease (HD) supports clinical development in ...
Benzinga.com

Vaccinex Faces Nasdaq Delisting: What's Going On With The Stock?

Vaccinex, Inc. (NASDAQ:VCNX) shares are trading lower after the company announced it received a delisting notification from the Nasdaq. Here’s what you need to know. What To Know: Vaccinex disclosed ...
Yahoo Finance

Vaccinex, Inc. to Present at the 12th Annual Jefferies London Healthcare Conference

Virtual presentation available Thursday, November 18 at 8:00am GMT/3:00am ET through Friday, November 19 at 5:00pm GMT / 12:00pm ET The presentation and a replay of the webcast will be available on ...
PharmiWeb

AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets

MOUNTAIN VIEW, CA / ACCESS Newswire / May 13, 2025 / AbTherx, Inc., a biotechnology company with innovative transgenic technologies that simplify and accelerate antibody discovery, today announced a ...
Seeking Alpha

Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC

ROCHESTER, N.Y., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vaccinex (VCNX), Inc. , a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease ...
Nasdaq

Vaccinex Announces Licensing of Anti-CCR8 Antibody to Surface Oncology

ROCHESTER, N.Y., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative ...
Seeking Alpha

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

Presentation title: Neoadjuvant biomarker trial of pepinemab to enhance nivolumab or ipilimumab activity in resectable head and neck cancer. Abstract 103. Time: 9:45-11:15 AM CST/10:45 AM – 12:15 PM ...
Nasdaq

Vaccinex Details Scientific Rationale for Expanding Pepinemab Clinical Programs to Include Alzheimer’s Disease

Oral presentation at the 12th Clinical Trials on Alzheimer's Disease Conference (CTAD 2019) describes similarities in degenerative processes of Huntington’s and Alzheimer’s Disease ROCHESTER, N.Y., ...
Business Insider

Vaccinex, Inc. Announces the First Patient Treated in a Phase Ib/II Combination Study with Anti-Semaphorin 4D Antibody, VX15/2503, and Avelumab in Non-Small Cell Lung Cancer ...

ROCHESTER, N.Y., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Vaccinex Inc. today announced the dosing of the first patient in a Phase Ib/II study of VX15/2503, an investigational humanized anti-semaphorin 4D ...
Benzinga.com

Why Vaccinex (VCNX) Stock Is Trading Lower

Vaccinex shares are trading lower by 7.1%Thursday morning. The company announced a 1-for-14 reverse stock split. Live on Wednesday: Historic Summer Setup: 3 "Power Patterns" Triggering in the next 75 ...
Business Insider

Vaccinex Announces Licensing of Anti-CCR8 Antibody to Surface Oncology

ROCHESTER, N.Y., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative ...